Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Q4 2025 earnings call transcript

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Q4 2025 Earnings Call Transcript February 5, 2026 Adaptive Biotechnologies ...

Adaptive Biotechnologies targets 30%+ clonoSEQ test volume growth in 2026 while expanding margins and data partnerships

Q4 2025 earnings call recap: clonoSEQ MRD growth, 2026 revenue guidance, margins, cash burn and risks—read now.

Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2025 Financial Results

Adaptive Biotechnologies Corporation ("Adaptive Biotechnologies") (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics ...
MarketersMEDIA Newsroom

Integrated Pipeline: Creative Biolabs Synergizes AI Neoantigen Prediction with NeoTCR-T and PD-1 Blockade Strategies

Recently, Creative Biolabs offered a unified framework to accelerate the development of highly specific, evasion-resistant ...